UBS Group Increases Henry Schein (NASDAQ:HSIC) Price Target to $87.00

Henry Schein (NASDAQ:HSIC) had its price objective hoisted by research analysts at UBS Group from $79.00 to $87.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group’s target price suggests a potential upside of 6.79% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the company. Barrington Research set a $97.00 price target on Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Wells Fargo & Company upped their price target on shares of Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Henry Schein presently has an average rating of “Hold” and a consensus price target of $85.58.

Henry Schein Price Performance

Henry Schein stock opened at $81.47 on Wednesday. Henry Schein has a 12-month low of $60.56 and a 12-month high of $89.29. The company has a current ratio of 1.38, a quick ratio of 0.79 and a debt-to-equity ratio of 0.59. The firm has a 50-day moving average price of $77.75 and a 200-day moving average price of $72.04. The firm has a market capitalization of $9.34 billion, a PE ratio of 24.91, a price-to-earnings-growth ratio of 2.43 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. The company had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities research analysts forecast that Henry Schein will post 4.74 EPS for the current year.

Institutional Trading of Henry Schein

Several hedge funds and other institutional investors have recently made changes to their positions in HSIC. MAI Capital Management grew its stake in Henry Schein by 7.5% during the 3rd quarter. MAI Capital Management now owns 2,061 shares of the company’s stock worth $137,000 after buying an additional 144 shares during the last quarter. CW Advisors LLC raised its stake in Henry Schein by 2.8% in the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock valued at $432,000 after buying an additional 163 shares during the last quarter. Truist Financial Corp boosted its holdings in Henry Schein by 3.3% in the third quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after acquiring an additional 175 shares in the last quarter. Simon Quick Advisors LLC grew its stake in shares of Henry Schein by 5.5% during the second quarter. Simon Quick Advisors LLC now owns 3,466 shares of the company’s stock worth $253,000 after acquiring an additional 182 shares during the last quarter. Finally, Claret Asset Management Corp increased its holdings in shares of Henry Schein by 6.3% during the second quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock valued at $232,000 after acquiring an additional 187 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

More Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 beat and constructive outlook — Henry Schein beat EPS and revenue estimates, cited a stable dental market and set FY‑2026 EPS guidance (5.23–5.37), supporting the bullish narrative. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Analyst upgrades and higher targets — Multiple firms raised price targets and ratings after results (notably JPMorgan to $92/overweight, UBS to $87, Mizuho/Wells Fargo lifts), signaling renewed conviction in growth and valuation support. These Analysts Increase Their Forecasts On Henry Schein After Upbeat Q4 Results
• Positive Sentiment: Independent upgrades/bullish research — Robert W. Baird upgraded HSIC and Leerink Partners published a forecast calling for strong price appreciation, adding to buying interest. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Neutral Sentiment: Stock technical/market reaction — HSIC hit a 52‑week high on the post‑earnings rally, which can attract momentum flows but also profit‑taking. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: Analysts reassessing story — Coverage notes that the company’s growth profile is changing and analysts are re-evaluating growth vs. valuation; this produces mixed revisions rather than uniform upgrades. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Negative Sentiment: Sell‑side concerns remain — Morgan Stanley (and its analyst coverage reflected on TipRanks) continues to flag margin pressure and valuation as reasons for a Sell/underweight view with a low price target (~$58–$61), which limits consensus upside and can weigh on the stock. Henry Schein: Solid Growth but Margin Pressures and Valuation Drive Sell Rating
• Neutral Sentiment: Full Q4 transcript available for detail — Investors can review management commentary in the earnings transcript for guidance nuance and margin discussion. Henry Schein (HSIC) Q4 2025 Earnings Transcript

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.